Governance

We are dedicated to maintaining strong corporate governance standards. We believe that our governance structure supports our ability to achieve our strategic goals and create sustainable value for our shareholders and stakeholders.

GSK Board on stage at AGM 2024, Jon Symonds speaks at podium, audience listens

Our corporate governance architecture

Our corporate governance architecture is designed to enhance the effectiveness of our Board and support their oversight of the GSK Leadership Team (GLT) in delivering our Ahead Together strategy. This framework supports a clear division of responsibilities, appropriate distribution of workload to focused Board committees, and highly committed Directors who are motivated to drive the success of the company.

Our evolving governance framework equips us to navigate industry challenges, maintain our license to operate and drive sustainable growth as a pure biopharma business.

CFO Julie Brown talks to Board Director Charles Bancroft, behind stands Vishal Sikka, Liz Anderson

Ahead Together oversight

Our Board focuses on priorities agreed for the year to support delivery of GSK’s corporate strategy encapsulated in our Ahead Together ambitions. Our Board and management agendas are completely aligned with a clear focus on the three time periods that management communicate on – financial performance to 2026, pipeline progress and business development to support the growth ambitions to 2031 as well as the science and technologies that support the long-term growth of the business beyond 2031.

Board Chair, man, Jon Symonds speaks to audience from podium at AGM

Prioritising engagement

We engage with stakeholders, to understand their expectations and our ever changing landscape. Through ongoing dialogue, we address emerging issues and make decisions to meet their needs. Our Board gathers stakeholder perspectives through multiple channels, including our committees, our leadership team, insights reports, investor discussions, and meetings such as the Annual Governance Meeting and AGM. Our CEO and CFO meet with investors, analysts, and journalists to present our half-year and full-year results. For dividend details, see our dividend calendar.

GSK Board members, Charles Bancroft, Hal Barron, Anne Beal on stage at AGM

Responsible business oversight

Responsible business is embedded in our strategy for sustainable performance and long-term growth. We track progress in six priority areas to build trust: access, global health and health security, environment, inclusion, ethical standards, and product governance. Our Corporate Responsibility Committee oversees and monitors GLT’s progress against these six priority areas to build trust. This includes regularly reviewing our Responsible Business Performance Rating and the detailed Rating metrics. Progress against our priority areas are published annually in our Responsible Business Performance Report.